MDMA, Cortisol and Memory

In search for the missing link between acute and long-term effects of MDMA-use on cognition: Cortisollevels and MDMA-induced memory impairment

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON26979

Enrollment

Registered

2008-08-26

Start date

2008-11-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Geheugenprestatie

Interventions

- Placebo + MDMA (75mg) - Metyrapone (750mg) + placebo - Metyrapone (750mg) + MDMA (75mg) - Placebo + Placebo Proefpersonen zullen 4 condities (testdagen) doorlopen. Op zo een testdag zullen ze

Eligibility

Inclusion criteria

Inclusion criteria: 1. Experience with the use of MDMA (maximally 10 times in total for novice users; minimally 100 times in total for heavy users and at least once in the past 12 months for both user groups) 2. Free from medication 3. Good physical health as determined by examination and laboratory analysis 4. Absence of any major medical (except OAC), endocrine and neurological condition 5. Normal weight, body mass index (weight/height2) between 18 and 28 kg/m2 6. Written Informed Consent

Exclusion criteria

Exclusion criteria: 1. History of drug abuse (other than the use of MDMA) or addiction 2. Women: Pregnancy or lactation, no use of oral contraception pill 3. Cardiovascular abnormalities as assessed by standard 12-lead ECG 4. Excessive drinking (> 20 alcoholic consumptions a week) 5. Hypertension (diastolic> 100; systolic> 170) 6. Current or history of psychiatric disorder

Design outcomes

Primary

Measure	Time frame
- Cognitive and neuro-endocrine measurements	—

Contacts

Public ContactK.P.C. Kuypers

P.O. Box 616

k.kuypers@psychology.unimaas.nl+31 (0)433881902

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)